Thomas Rupp

Managing Director at Axolabs Berlin GmbH

Speaker

Thomas is Managing Director of LGC Axolabs Berlin GmbH, a newly established CDMO for Pilot and Process scale manufacturing of oligonucleotides. Since mid 2013 he is also Principal at Thomas Rupp Consulting with a strong focus on all aspects around synthetic RNA Therapeutics, specifically CMC, Technology assessment, Process development and optimization, and Facility design.

In 1985, he entered the world of synthetic nucleic acids in the research group of Nobel Laureate Prof. Harald zur Haussen at the German Cancer Research Center in Heidelberg, Germany, by setting-up the first core-facility for oligonucleotide synthesis and DNA sequencing in Europe. During this time, Thomas complimented his chemistry background with molecular biology and virology. Since then, Thomas stayed in the oligonucleotide field and besides development of DNA synthesis instrumentation, a PCR-machine and co-development of a DNA sequencer, he gained profound knowledge in GMP manufacturing, and related CMC-aspects.